ALBUMIN (HUMAN) 5% SOLUTION, USP

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

ALBUMIN (HUMAN)

Inapatikana kutoka:

GRIFOLS THERAPEUTICS LLC

ATC kanuni:

B05AA01

INN (Jina la Kimataifa):

ALBUMIN

Kipimo:

5%

Dawa fomu:

SOLUTION

Tungo:

ALBUMIN (HUMAN) 5%

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

50/250/500ML

Dawa ya aina:

Schedule D

Eneo la matibabu:

BLOOD DERIVATIVES

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0131452001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2005-07-11

Tabia za bidhaa

_ _
Page 1 of 17
PRODUCT MONOGRAPH
ALBUMIN (HUMAN) 5% SOLUTION, USP
Albumin (Human) 5%, USP
Intravenous Solution, 5%
Manufacturer’s Standard
Plasma Substitute/Blood Derivative
Manufactured by:
Grifols Therapeutics Inc.
8368 U.S. 70 Bus. Hwy West
Clayton, North Carolina
27520
U.S.A.
Imported and Distributed by:
Grifols Canada Ltd.
5060 Spectrum Way,
Suite 405
Mississauga, Ontario
L4W 5N5
Prepared for:
Canadian Blood Services
and/or
Héma-Québec
Submission Control No: 202697 Date of Approval: August 22, 2017
_ _
Page 2 of 17
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
DESCRIPTION....................................................................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
..........................................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
.......................